SBTi Verifies GenScript Biotech Corp’s Carbon Emission Reduction Goals, Marking a Major Sustainability Milestone!
PISCATAWAY, N.J., Feb. 18, 2025 /PRNewswire/ -- GenScript Biotech Corp, a global leader in life sciences R&D and manufacturing services, today announced that it is committing to aggressive carbon emission reduction targets. These targets have been verified by the Science Based Targets initiative (SBTi), aligning closely with the 1.5°C warming pathway outlined in the Paris Agreement. This certification highlights...
CJ Bioscience to Present Preclinical Data on Inflammatory Bowel Disease Pipeline Candidate CJRB-201 at ‘ECCO 2025’; Clinical Entry Targeted for 2026
'CJRB-201', a proprietary strain of Faecalibacterium with potent its anti-inflammatory effects, has demonstrated the strongest induction of regulatory T cells (Tregs) among analyzed strains. Preclinical studies in multiple animal models confirm significant improvements in key disease indicators, including inhibition of weight loss and improvement in disease activity index. Offering a differentiated therapeutic option, CJRB-201 has shown preclinical efficacy...
TAHO Pharmaceuticals Reports Positive Results from Pivotal Study of TAH3311, the First Oral Dissolving Film Anticoagulant
TAIPEI, Feb. 17, 2025 /PRNewswire/ -- TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's first Apixaban oral dissolving film (ODF). The study confirmed that TAH3311 is bioequivalent to U.S. and European reference Apixaban tablets (Eliquis®) under fasting conditions, with Cmax and AUC values falling within the regulatory acceptance range (80-125%). The study enrolled...
3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy
REYKJAVIK, Iceland, Feb. 17, 2025 /PRNewswire/ -- 3Z Pharmaceuticals today announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positions the mechanisms engaged by amlodipine, an L-type calcium channel blocker (LTCC), as a foundation for a novel therapy for ADHD. The findings provide robust validation of 3Z's cutting-edge high-throughput drug discovery platform and introduce...
Singapore launches Mental Health Innovation Asia Hub at international symposium
High demand: Mental health now tops health concerns in Singapore, surpassing cancer and COVID-19. New regional hub: MHIN Asia Hub, based in Singapore, aims to share innovative resources and ideas to promote mental health support across Asia. SINGAPORE, Feb. 17, 2025 /PRNewswire/ -- In a significant advancement for mental health care, the SingHealth Duke-NUS Global Health Institute, in...
Fosun Pharmaceutical Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation
SHANGHAI, Feb. 17, 2025 /PRNewswire/ -- Nowadays, artificial intelligence (AI) technology is profoundly reshaping the landscape of the pharmaceutical and healthcare industry. As a global innovation-driven pharmaceutical and healthcare group, Fosun Pharma places great emphasis on the transformative potential of AI technology in the pharmaceutical and healthcare sectors. The company actively embraces AI technology, deploying it in areas such as...
Baltics leading pharmaceutical company Grindeks expands to new export markets worldwide
RIGA, Latvia, Feb. 17, 2025 /PRNewswire/ -- The leading pharmaceutical company in the Baltics, Grindeks, continues to strengthen its global presence by entering new export markets. This year, for the first time, Grindeks products will be delivered to Panama. The company's export markets already include countries such as Chile, Mexico, Australia, Singapore,...
Minish Holds First Seminar in Japan with Great Success – Over 100 Dentists in Attendance
"Impressed by Extensive Full-Mouth Rehabilitation Cases" , "Anti-Aging Effects Highly Praised" TOKYO, Feb. 17, 2025 /PRNewswire/ -- On the 17th, Minish Technology successfully concluded its first-ever clinical case seminar and corporate presentation in Japan. The event, held the previous day at Shiodome Season Terrace in Minato City, Tokyo, drew over 100 dentists from across the country, demonstrating significant interest...
Stryker launches ProCeed hospital bed
New hospital bed helps caregivers deliver efficient and quality care in markets outside the U.S. PORTAGE, Mich., Feb. 17, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced the launch of the ProCeed hospital bed, offering simplicity while enhancing care across various regions. New ProCeed hospital bed...
Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, Feb. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that its first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, IBI363, has received its second Fast Track Designation (FTD)...
